CliffBio
small molecule

VOCABRIA

CABOTEGRAVIR SODIUM

Loss of exclusivityFebruary 2031latest FDA-listed patent expiry
CompanyViiV Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameVOCABRIA
Active ingredientCABOTEGRAVIR SODIUM
StrengthEQ 30MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2021
Marketing statusRX

Listed patents

PatentExpiresType
8410103February 2031substance, product
10927129April 2026substance, product

Regulatory exclusivity

CodeExpires
NCEJanuary 2026

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VOCABRIA patent cliff — loss of exclusivity February 2031 | CliffBio